Literature DB >> 27336295

(18)F- and (68)Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1.

Simone Maschauer1, Jürgen Einsiedel2, Harald Hübner2, Peter Gmeiner2, Olaf Prante1.   

Abstract

The neurotensin (NT) receptor-1 (NTS1) is overexpressed in a variety of carcinomas and is therefore an interesting target for imaging with positron emission tomography (PET). The aim of this study was the development of new NT derivatives based on the metabolically stable peptide sequence NLys-Lys-Pro-Tyr-Tle-Leu suitable for PET imaging. The NT peptides were synthesized by solid-phase supported peptide synthesis and elongated with respective chelators (NODA-GA, DOTA) for (68)Ga-labeling or propargylglycine for (18)F-labeling via copper-catalyzed azide-alkyne cycloaddition. Receptor affinities of the peptides for NTS1 were in the range of 19-110 nM. Biodistribution studies using HT29 tumor-bearing mice showed highest tumor uptake for [(68)Ga]6 and [(68)Ga]8 and specific binding in small-animal PET studies. The tumor uptake of (68)Ga-labeled peptides in vivo significantly correlated with the in vitro Ki values for NTS1. [(68)Ga]8 displayed an excellent tumor-to-background ratio and could therefore be considered as an appropriate molecular probe for NTS1 imaging by PET.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27336295     DOI: 10.1021/acs.jmedchem.6b00675

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.

Authors:  Xiaoqin Yin; Mengzhe Wang; Hui Wang; Huaifu Deng; Tingting He; Yue Tan; Zehua Zhu; Zhanhong Wu; Shuo Hu; Zibo Li
Journal:  Amino Acids       Date:  2017-05-23       Impact factor: 3.520

3.  Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2022-03-08       Impact factor: 6.514

4.  Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.

Authors:  Clément Morgat; Véronique Brouste; Adrien Chastel; Valérie Vélasco; Gaétan Macgrogan; Elif Hindié
Journal:  Breast Cancer Res Treat       Date:  2021-10-01       Impact factor: 4.872

5.  Neurotensin analogs by fluoroglycosylation at Nω-carbamoylated arginines for PET imaging of NTS1-positive tumors.

Authors:  Lisa Schindler; Katrin Wohlfahrt; Lara Gluhacevic von Krüchten; Olaf Prante; Max Keller; Simone Maschauer
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

6.  Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors.

Authors:  Lisa Schindler; Jutta Moosbauer; Daniel Schmidt; Thilo Spruss; Lukas Grätz; Steffen Lüdeke; Frank Hofheinz; Sebastian Meister; Bernd Echtenacher; Günther Bernhardt; Jens Pietzsch; Dirk Hellwig; Max Keller
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

7.  Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors.

Authors:  Simone Maschauer; Jürgen Einsiedel; Dominik Reich; Harald Hübner; Peter Gmeiner; Hans-Jürgen Wester; Olaf Prante; Johannes Notni
Journal:  Pharmaceuticals (Basel)       Date:  2017-03-10

Review 8.  Translational molecular imaging in exocrine pancreatic cancer.

Authors:  Bart Cornelissen; James C Knight; Somnath Mukherjee; Laura Evangelista; Catarina Xavier; Federico Caobelli; Silvana Del Vecchio; Latifa Rbah-Vidal; Jacques Barbet; Marion de Jong; Fijs W B van Leeuwen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-17       Impact factor: 9.236

Review 9.  Utilizing Peptide Ligand GPCRs to Image and Treat Pancreatic Cancer.

Authors:  Gail L Matters; John F Harms
Journal:  Biomedicines       Date:  2018-06-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.